BIIB
Biogen-IDEC Corporation

Choosing a Biotech Stock 3: Biogen Idec [September 14, 2007 blog]
Rituxan and Zevalin, A Cautionary Tale [July 14, 2007 at New York Times, registration required]
Biogen Idec and Tysabri [May 6, 2007 blog]

Next conference date: July 22, 2008 @ 5:30 AM Pacific Time

Analyst Conference Summaries available:

2008
BIIB analyst conference summary Q1 2008
BIIB analyst conference summary Q2 2008
04/23/2008
07/22/2008
Q1
Q2
2007
BIIB Q4 2007 analyst conference summary
BIIB Q3 2007 conference summary
biib Q2 2007
BIIB summary
02/06/2008
10/23/2007
07/24/2007
05/02/2007
Q4
Q3
Q2
Q1
2006
02/15/2007
10/31/2006
07/26/2006
04/26/2006
Q4
Q3
Q2
Q1

First acquired on February 6, 2008

Biogen-Idec is a biotechnology pharmaceutical company which markets Rituxan, Zevalin, Avonex, Fumaderm, and Tysabri.

Biogen-Idec Web site:

main page
investor page

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. Before making or terminating an investment you should always verify any factual basis of your decision.